| Literature DB >> 31696918 |
Elise M van Praag1, Merel E Stellingwerf1, Jarmila D W van der Bilt1, Wilhelmus A Bemelman1, Krisztina B Gecse2, Christianne J Buskens1.
Abstract
BACKGROUND AND AIMS: Ligation of the intersphincteric fistula tract [LIFT] and advancement flap [AF] procedures are well-established, sphincter-preserving procedures for closure of high perianal fistulas. As surgical fistula closure is not commonly offered in Crohn's disease patients, long-term data are limited. This study aims to evaluate outcomes after LIFT and AF in Crohn's high perianal fistulas.Entities:
Keywords: Crohn’s disease; Perianal fistula; surgery
Mesh:
Substances:
Year: 2020 PMID: 31696918 PMCID: PMC7346888 DOI: 10.1093/ecco-jcc/jjz181
Source DB: PubMed Journal: J Crohns Colitis ISSN: 1873-9946 Impact factor: 9.071
Patient demographics
| LIFT [ | AF [ | |
|---|---|---|
| Male sex, | 6 [31.6] | 9 [42.9] |
| Age, yearsa | 34.5 [21.1–75.5] | 33.3 [19.2–67.2] |
| History of smoking, | 11 [57.9] | 9 [42.9] |
| Smoking at moment of surgery,b | 7 [36.8] | 4 [19.0] |
| Familial inflammatory bowel disease, | 5 [26.3] | 5 [23.8] |
| Stoma, | 4 [21.1] | 5 [23.8] |
| Location of Crohn’s disease, | ||
| L1 Ileum | 6 [31.6] | 5 [23.8] |
| L2 Colon | 2 [10.5] | 6 [28.6] |
| L3 Both | 5 [26.3] | 3 [14.3] |
| Missing | 6 [31.6] | 7 [33.3] |
| Use of anti-TNF, | 15 [78.9] | 9 [42.9] |
| Infliximab | 8 [42.1] | 4 [19.0] |
| Adalimumab | 7 [36.8] | 5 [23.8] |
| Use of immunomodulators, | 10 [52.6] | 9 [42.9] |
| Azathioprine | 4 [21.1] | 4 [19.0] |
| Methotrexaat | 0 [0.0] | 2 [9.5] |
| Mercaptopurine | 6 [31.6] | 3 [14.3] |
| Use of anti-TNF and/or immunomodulators, | 16 [84.2] | 12 [57.1] |
| Use of trial medication, | 2 [10.5] | 0 [0.0] |
| Tacrolimus | 1 [5.3] | 0 [0.0] |
| Vedolizumab | 1 [5.3] | 0 [0.0] |
| Preoperative seton drainage, monthsa | 4.9 [2.1–26.1] | 3.7 [1.4–113.7] |
| Time of procedure, minutesa | 74.0 [27–224] | 62.0 [39–125]- |
| Previous surgical closure,c | 6 [31.6] | 3 [14.3] |
| >12 months of follow-up, | 9 [47.4] | 19 [90.5] |
| Number of internal openingsa | 1 [1–2] | 1 [1–2] |
| Number of external openingsa | 1 [1–2] | 1 [0–5] |
| Number of recurrent fistulas, | 4 [21.1] | 5 [23.8] |
Abbreviations: LIFT, ligation of the intersphincteric fistula tract; AF, advancement flap; TNF, tumour necrosis factor.
aValues are median [range].
bOr within 3 months prior to surgery.
cPrevious attempt at surgical closure of the fistula tract [LIFT, AF, plug or other].
Clinical healing
| Combined | LIFT | AF | |||||||
|---|---|---|---|---|---|---|---|---|---|
| No clinical healing [ | Clinical healing [ |
| No clinical healing [ | Clinical healing [ |
| No clinical healing [ | Clinical healing [ |
| |
| Male sex, | 5 [50.0] | 10 [34.5] | 0.388 | 1 [50.0] | 5 [29.4] | 0.562 | 4 [50.0] | 5 [41.7] | 0.714 |
| Age, yearsa | 40.6 [23.9–55.2] | 33.3 [19.2–75.5] | 0.349 | 43.2 [32.6–53.8] | 34.5 [21.1–75.5] | 0.558 | 40.6 [23.9–55.2] | 27.4 [19.2–67.2] | 0.419 |
| History of smoking, | 5 [50.0] | 15 [51.7] | 0.846 | 2 [100.0] | 9 [52.9] | 0.845 | 3 [37.5] | 6 [50.0] | 0.583 |
| Smoking at moment of surgery,b | 1 [10.0] | 10 [34.5] | 0.535 | 0 [0.0] | 7[41.2] | 0.998 | 1[12.5] | 3 [25.0] | 0.746 |
| Familial inflammatory bowel disease, | 2 [20.0] | 7 [24.1] | 0.940 | 0 [0.0] | 5 [29.4] | 0.999 | 2 [25.0] | 2 [16.7] | 0.999 |
| Stoma, | 3 [30.0] | 6 [20.7] | 0.549 | 0 [0.0] | 4 [23.5] | 0.999 | 3 [37.5] | 2 [16.7] | 0.302 |
| Preoperative seton drainage, monthsa | 4.0 [1.9 – 8.1] | 4.5 [1.4 – 26.1] | 0.185 | 4.7 [4.6–4.9] | 5.5 [2.1–26.1] | 0.462 | 3.2 [1.9–8.1] | 3.7 [1.4–14.5] | 0.461 |
| Anti-TNF, | 5 [50.0] | 19 [65.5] | 0.388 | 2 [100.0] | 13 [76.5] | 0.999 | 3 [37.5] | 6 [50.0] | 0.583 |
| Anti-TNF and/or immunomodulators, | 5 [50.0] | 23 [79.3] | 0.085 | 2 [100.0] | 14 [82.4] | 0.999 | 3 [37.5] | 9 [75.0] | 0.104 |
| Previous surgical closure,c | 2 [20.0] | 7 [24.1] | 0.789 | 0 [0.0] | 6 [35.3] | 0.999 | 2 [25.0] | 1 [8.3] | 0.327 |
Abbreviations: LIFT, ligation of the intersphincteric fistula tract; AF, advancement flap; TNF, tumour necrosis factor.
aValues are median [range].
bOr within 3 months prior to surgery.
cPrevious attempt at surgical closure of the fistula tract [LIFT, AF, plug or other].
Radiological healing
| Combined | LIFT | AF | |||||||
|---|---|---|---|---|---|---|---|---|---|
| No radio healing [ | Radio healing [ |
| No radio healing [ | Radio healing [ |
| No radio healing [ | Radio healing [ |
| |
| Male sex, | 7 [35.0] | 8 [40.0] | 0.744 | 3 [33.3] | 3 [30.0] | 0.876 | 4 [36.4] | 5 [50.0] | 0.530 |
| Age, yearsa | 39.8 [19.2–75.5] | 29.8 [19.9–67.2] | 0.089 | 40.3 [24.4–75.5] | 29.8 [21.1–45.0] | 0.016 | 37.6 [19.2–55.2] | 30.1 [19.9–67.2] | 0.855 |
| History of smoking, | 13 [65.0] | 7 [35.0] | 0.997 | 8 [88.9] | 3 [30.0] | 0.603 | 5 [45.5] | 4 [40.0] | 0.654 |
| Smoking at moment of surgery,b | 7 [35.0] | 4 [20.0] | 0.079 | 4 [44.4] | 3 [30.0] | 0.026 | 3 [27.3] | 1 [10.0] |
|
| Anti-TNF, | 10 [50.0] | 14 [70.0] | 0.201 | 7 [77.8] | 8 [80.0] | 0.906 | 3 [27.3] | 6 [60.0] | 0.138 |
| Anti-TNF and/or immunomodulators, | 11 [55.0] | 17 [85.0] | 0.047 | 7 [77.8] | 9 [90.0] | 0.476 | 4 [36.4] | 8 [80.0] | 0.054 |
Abbreviations: LIFT, ligation of the intersphincteric fistula tract; AF, advancement flap; TNF, tumour necrosis factor.
aValues are median [range].
bOr within 3 months prior to surgery.
Figure 1.Kaplan–Meier plot of recurrence-free survival after LIFT [n = 19] and AF [n = 21]. LIFT, ligation of the intersphincteric fistula tract; AF, advancement flap.
Recurrence
| Combined | LIFT | AF | |||||||
|---|---|---|---|---|---|---|---|---|---|
| No recur. [ | Recur. [ | Sign. | No recur. [ | Recur. [ | Sign. | No recur. [ | Recur. [ | Sign. | |
| Male sex, | 13 [40.6] | 2 [25.0] | 0.420 | 5 [33.3] | 1 [25.0] | 0.751 | 8 [47.1] | 1 [25.0] | 0.434 |
| Age, yearsa | 33.0 [19.9–67.2] | 42.4 [19.2–75.5] | 0.101 | 32.6 [21.1–53.8] | 52.3 [40.3–75.5] | 0.002 | 33.3 [19.9–67.2] | 34.9 [19.2–49.8] | 0.675 |
| History of smoking, | 13 [40.6] | 7 [87.5] | 0.311 | 7 [46.7] | 4 [100.0] | 0.762 | 6 [35.3] | 3 [75.0] | 0.979 |
| Smoking at moment of surgery,b | 6 [18.8] | 5 [62.5] | 0.073 | 5 [33.3%] | 2 [50.0] | 0.079 | 1 [5.9] | 3 [75.0] | 0.511 |
| Anti-TNF, | 21 [65.6] | 3 [37.5] | 0.158 | 13 [86.7] | 2 [50.0] | 0.136 | 8 [47.1] | 1 [25.0] | 0.434 |
| Anti-TNF and/or immunomodulators, | 24 [75.0] | 4 [50.0] | 0.178 | 14 [93.3] | 2 [50.0] | 0.067 | 10 [58.8] | 2 [50.0] | 0.749 |
Abbreviations: LIFT, ligation of the intersphincteric fistula tract; AF, advancement flap; Recur., recurrence; TNF, tumour necrosis factor.
aValues are median [range].
bOr within 3 months prior to surgery.